Re: Investing ViroLogic (VLGC)# Investment - 投资
v*x
1 楼
small biopharm companies are usually totally different species
from most other growth stocks. they are mostly event driven and
less likely be affected by market trend. so I don't know if
your criteria fit well for this sector.
as for VLGC, the selling point is anti-viral assay. If I remember
correctly, CDC's '02 figure for this market is about $300 million.
Major players are those big pharmas such as JNJ, LLY, ABT, etc.
For what I read (patent search), VLGC's pipeline does not have
much niche st
from most other growth stocks. they are mostly event driven and
less likely be affected by market trend. so I don't know if
your criteria fit well for this sector.
as for VLGC, the selling point is anti-viral assay. If I remember
correctly, CDC's '02 figure for this market is about $300 million.
Major players are those big pharmas such as JNJ, LLY, ABT, etc.
For what I read (patent search), VLGC's pipeline does not have
much niche st